Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Sanofi, Sanofi en nog eens Sanofi

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Sanofi, Sanofi en nog eens Sanofi

785 Posts
Pagina: «« 1 2 3 4 5 6 ... 40 »» | Laatste | Omlaag ↓
  3. [verwijderd] 9 februari 2009 22:16
    online.wsj.com/article/BT-CO-20090209...

    thnx robbie2 @ erik.com

    LONDON (Dow Jones)--Sanofi-Aventis SA's (SNY) Chief Executive Chris Viehbacher is this week set to unveil his vision for the future of the world's third-largest drugmaker, in an event that is expected to overshadow the Paris-based company's fourth-quarter earnings. In his first outing after taking the helm of Sanofi-Aventis on Dec. 1, Viehbacher is expected when presenting the group's fourth-quarter results on Wednesday to comment on whether he's looking at large mergers and acquisitions to provide an immediate sales boost, or whether he has identified smaller, targeted acquisitions as part of a long-term approach to boost flagging growth. The French drugmaker is "in dire need for strategic redirection," according to Deutsche Bank analysts. Generic competition is looming for its top-selling drugs, blockbusters Lovenox and Plavix, while there are few promising experimental drugs in its pipeline, with the exception of heart treatment Multaq. Like its peers, Sanofi-Aventis looks set to turn to acquisitions to overcome the patent loss of its key revenue-driving drugs. Since its inception as a unit of oil company Elf Aquitaine in the early 1970s, Sanofi-Aventis has grown through a series of acquisitions engineered by Chairman Jean-Francois Dehecq, culminating in the 2004 merger of Aventis SA with Sanofi-Synthelabo, which catapulted the company into the world's top third position. Although it's not expected to unveil plans for new huge merger, speculation over French group's interest in U.S. marketing partner Bristol-Myers Squibb Co. (BMY) has grown since World No. 1 Pfizer Inc (PFE) announced it intends to buy smaller rival Wyeth (WYE). Bernstein analyst Tim Anderson said in a recent note to investors that Viebacher is too new to the job to make an immediate run for Bristol-Myers Squibb. Anderson also noted that, with both Pfizer and Roche Holding AG (ROG.VX) lining up funding for their own respective big deals, there may not be enough funds to go around to facilitate yet a third large transaction. "In other words, in the near-to-intermediate-term at least, we don't believe Sanofi-Aventis is likely to bid on Bristol-Myers Squibb," Anderson added. Given Viehbacher's experience at GlaxoSmithKline PLC (GSK), which in recent years has privileged smaller acquisitions in key areas over large transactions, he may opt for targeted bolt-on purchases. According to trade union sources quoted in the French media, Viehbacher has told employees that the company is preparing to diversify its operations with a focus on non-prescription drugs, vaccines as well as cancer drugs, in addition to boosting its pipeline through acquisitions. The same sources said Sanofi-Aventis can draw on resources worth EUR4 billion for any eventual deals.
  4. [verwijderd] 9 februari 2009 22:21
    * Drugmaker Piramal Healthcare (PIRA.BO) fell 1 percent to
    192.55 rupees, after rising nearly 25 percent on reports
    GlaxoSmithKline Plc (GSK.L) and Sanofi Aventis SA (SASY.PA)
    have emerged as bidders for the company. Piramal denied the
    reports

    uk.reuters.com/article/rbssFinancialS...
  7. [verwijderd] 9 februari 2009 22:31
    By Gregory Viscusi
    Feb. 9 (Bloomberg) -- Sanofi-Aventis SA Chief Executive
    Officer Chris Viehbacher plans to spend 20 percent of his time
    looking for acquisitions and is considering outsourcing research,
    Les Echos said, citing an interview with him.
    The acquisitions he’s looking for are mostly in developing
    countries or in expanding activities such as non-prescription
    drugs, the French financial daily said. The price for Crucell NV,
    a Dutch vaccine maker Sanofi had considered buying, has risen so
    much “it makes me cough,” Les Echos quoted him as saying.
  10. gogogoo 9 februari 2009 23:08
    quote:

    willemn schreef:

    By Gregory Viscusi
    Feb. 9 (Bloomberg) -- Sanofi-Aventis SA Chief Executive
    Officer Chris Viehbacher plans to spend 20 percent of his time
    looking for acquisitions and is considering outsourcing research,
    Les Echos said, citing an interview with him.
    The acquisitions he’s looking for are mostly in developing
    countries or in expanding activities such as non-prescription
    drugs, the French financial daily said. The price for Crucell NV,
    a Dutch vaccine maker Sanofi had considered buying, has risen so
    much “it makes me cough,” Les Echos quoted him as saying.
    De 2e posting in de dagdraad.
  14. forum rang 4 aossa 10 februari 2009 12:22
    quote:

    willemn schreef:

    daar wordt ook niks gezegd
    O, ik verwacht toch wat te vernemen over de voortgang cq vooruitzichten van Flu-cell en Rabies vaccinnes.

    En ook wat de CEO niet vertelt interesseert mij ;-)

    Chris Viehbacher heeft pas zijn analyse gemaakt betreffende het bedrijf Sanofi-Aventis, laten we kijken wat hij morgen te vertellen (en niet te vertellen) heeft.
    Imo is de monsterfusie van weleer nog niet helemaal verteerd.

    2008 Full-Year Results & Outlook
    February 11, 2009

    7:30 am CET: press release available online
    2:00-4:00 pm CET: live video webcast of the presentation to the financial community including a question & answer session with the audience, in English with simultaneous translation in French.
  15. forum rang 4 aossa 10 februari 2009 12:31
    (CercleFinance.com) - Sanofi-Aventis a pris la première place du palmarès des plus fortes hausses du CAC 40 mardi à la veille de la publication de ses résultats 2008 et de la présentation de ses perspectives.

    Le consensus s'attend à ce que le groupe pharmaceutique fasse part d'un bénéfice par action (BPA) annuel de 5,48 dollars pour un résultat opérationnel courant de 9.756 millions d'euros et un chiffre d'affaires de 27.519 millions.

    Concernant 2009, le marché pronostique à l'heure actuelle un BPA de 5,81 euros, soit une croissance de l'ordre de 6%.

    Pour les analystes, le rendez-vous de demain sera surtout l'occasion pour Chris Viehbacher, le nouveau directeur général, de dévoiler sa vision pour le groupe.

    'Nous pensons toutefois qu'il est trop tôt pour que le groupe dévoile un plan détaillé en matière de stratégie ou de restructuration', indique un analyste basé à Londres.
  16. k61 10 februari 2009 12:38
    quote:

    willemn schreef:

    bij de aankondiging van cijfers van alle Pharma jongens werd hier gesteld dat er wel eens wat gezegd zou kunnen worden over Crucell.

    is nergens gebeurd.

    nou is morgen de laatste aan de beurt.

    en?

    daar wordt ook niks gezegd

    over en sluiten

    donderdag flink down.
    BLA,BLA,BLA,Lapzwans
  20. [verwijderd] 11 februari 2009 07:42
    Sanofi-aventis Delivers 2008 Results Above Guidance

    2008 performance

    - EPS2 growth at constant euro/dollar exchange rates above guidance (up 11.2% against guidance of around 9%)
    - Solid sales performance driven by Lantus® (up 27.7%), Taxotere® (up 13.2%), Lovenox® (up 10.6%), Plavix® (up 10.5%), Aprovel® (up 14.2%) and vaccines (up 9.6%)
    - Successful launch of Pentacel® and filing for approval of Multaq® and Ciltyri® in the United States and Europe
    - Growth ahead of the market in the United States, and double-digit growth in emerging markets and in Japan
    - Continued improvement in operating ratios
    - Net debt reduced to €1.8 billion
    - Proposed dividend of €2.20 per share, payable April 28, 2009

    2009 guidance

    In 2009, sanofi-aventis expects growth in adjusted EPS excluding selected items1 of at least 7% at constant exchange rates, barring major adverse events such as the launch of a generic of Lovenox® in the United States
785 Posts
Pagina: «« 1 2 3 4 5 6 ... 40 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 913,39 +0,30%
EUR/USD 1,0892 +0,68%
FTSE 100 8.445,80 +0,21%
Germany40^ 18.875,90 +0,03%
Gold spot 2.393,40 +0,29%
NY-Nasdaq Composite 16.742,39 +1,40%

Stijgers

INPOST
+6,22%
NX FIL...
+6,15%
JDE PE...
+4,86%
WDP
+4,26%
ASMI
+2,87%

Dalers

ABN AM...
-6,11%
AMG Cr...
-3,25%
Air Fr...
-3,06%
Fugro
-2,30%
Pharming
-2,07%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!